VC: Gemin X leads with $65M second round

Gemin X leads with $65M second round.






Gemin X

second round

H.I.G., Sanderling

Funding will support Gemin X's continued clinical development of lead product candidate GX15-070, including an ongoing Phase I/II trial in patients with chronic lymphocytic leukemia and a Phase I trial in patients with solid tumors.

Abingdon, UK

second round

MPM Capital

The funds will advance Oxagen's small molecule anti-inflammatory for asthma to the clinic and expand the company's clinical and pre-clinical stage portfolio.

San Diego

second round

JPMorgan Partners, Delphi Ventures

The money will allow Phenomix to steer its lead drug into human trials.

Cylene Pharmaceuticals
San Diego

second round

Coastview Capital

The funding will allow Cylene to advance CX-3543, its lead product for the treatment of multiple cancers, into clinical development.

Aperon Biosystems
Palo Alto, CA

second round

Canaan Partners

Aperon is developing an in-home monitor for daily measurement of exhaled nitric oxide for the management of asthma.

Innovative Biosensors
College Park, MD

first round

Harbert Venture Partners

Innovative Biosensors is developing technologies for the rapid detection of pathogens.

Suggested Articles

Avidity Biosciences is on a roll—after inking an R&D deal with Eli Lilly and hiring a new CEO, the company is reeling in $100 million.

What the NASH field needs, says Genfit CEO Pascal Prigent, is something like the Hb1Ac test for diabetes.

Blocking a newly discovered molecule produced by B cells could slow their flow into the brain and offer a new way to treat MS, a Canadian team found.